N-Acetyl-D-mannosamineCAS# 7772-94-3 |
- 2-Acetamido-2-deoxy-D-glucose
Catalog No.:BCC8508
CAS No.:7512-17-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 7772-94-3 | SDF | Download SDF |
PubChem ID | 11096158 | Appearance | Powder |
Formula | C8H15NO6 | M.Wt | 221.21 |
Type of Compound | Impurities | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | N-[(2R,3S,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide | ||
SMILES | CC(=O)NC1C(C(C(OC1O)CO)O)O | ||
Standard InChIKey | OVRNDRQMDRJTHS-OZRXBMAMSA-N | ||
Standard InChI | InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5+,6-,7-,8-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
N-Acetyl-D-mannosamine Dilution Calculator
N-Acetyl-D-mannosamine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.5206 mL | 22.603 mL | 45.2059 mL | 90.4118 mL | 113.0148 mL |
5 mM | 0.9041 mL | 4.5206 mL | 9.0412 mL | 18.0824 mL | 22.603 mL |
10 mM | 0.4521 mL | 2.2603 mL | 4.5206 mL | 9.0412 mL | 11.3015 mL |
50 mM | 0.0904 mL | 0.4521 mL | 0.9041 mL | 1.8082 mL | 2.2603 mL |
100 mM | 0.0452 mL | 0.226 mL | 0.4521 mL | 0.9041 mL | 1.1301 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- N-acetyl-D-galactosamine
Catalog No.:BCX0512
CAS No.:1811-31-0
- D-Galactosamine hydrochloride
Catalog No.:BCX0511
CAS No.:1772-03-8
- D-Mannosamine hydrochloride
Catalog No.:BCX0510
CAS No.:5505-63-5
- Moracin N
Catalog No.:BCX0509
CAS No.:135248-05-4
- (S)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-7-phenylheptan-3-one
Catalog No.:BCX0508
CAS No.:1220110-76-8
- 1β-Hydroxy-8α-methoxyeremophila-7(11),9-dien-12,8β-olide
Catalog No.:BCX0507
CAS No.:849700-45-4
- Methylconiferin
Catalog No.:BCX0506
CAS No.:883150-46-7
- Iristectorin B
Catalog No.:BCX0505
CAS No.:94396-09-5
- Vavain
Catalog No.:BCX0504
CAS No.:199996-77-5
- 6-Demethoxyirigenin
Catalog No.:BCX0503
CAS No.:1348833-10-2
- Oxyphyllenodiol A
Catalog No.:BCX0502
CAS No.:363610-30-4
- Teuhetenone A
Catalog No.:BCX0501
CAS No.:152481-80-6
- Xanthomicrol
Catalog No.:BCX0514
CAS No.:16545-23-6
- 5,7-Dihydroxy-3,8,3',4'-tetramethoxyflavone
Catalog No.:BCX0515
CAS No.:42923-42-2
- 5,4'-Dihydroxy-6,7,8,3'-tetramethoxyflavone
Catalog No.:BCX0516
CAS No.:16520-78-8
- Tetrahydroauroglaucin
Catalog No.:BCX0517
CAS No.:40434-07-9
- Sanggenon F
Catalog No.:BCX0518
CAS No.:85889-03-8
- 4-Hydroxyphenylpyruvic acid
Catalog No.:BCX0519
CAS No.:156-39-8
- Isodihydroauroglaucin
Catalog No.:BCX0520
CAS No.:74886-31-0
- Demethoxysudachitin
Catalog No.:BCX0521
CAS No.:4323-80-2
- Oxyphyllenodiol B
Catalog No.:BCX0522
CAS No.:363610-32-6
- Labda-12E,14-dien-16,15-olid-17-oic acid
Catalog No.:BCX0523
CAS No.:1855905-16-6
- Butyl rosmarinate
Catalog No.:BCX0524
CAS No.:222713-83-9
- Dihydroauroglaucin
Catalog No.:BCX0525
CAS No.:77102-91-1
Integrative analysis with microbial modelling and machine learning uncovers potential alleviators for ulcerative colitis.[Pubmed:38563656]
Gut Microbes. 2024 Jan-Dec;16(1):2336877.
Ulcerative colitis (UC) is a challenging form of inflammatory bowel disease, and its etiology is intricately linked to disturbances in the gut microbiome. To identify the potential alleviators of UC, we employed an integrative analysis combining microbial community modeling with advanced machine learning techniques. Using metagenomics data sourced from the Integrated Human Microbiome Project, we constructed individualized microbiome community models for each participant. Our analysis highlighted a significant decline in both alpha and beta-diversity of strain-level microbial populations in UC subjects compared to controls. Distinct differences were also observed in the predicted fecal metabolite profiles and strain-to-metabolite contributions between the two groups. Using tree-based machine learning models, we successfully identified specific microbial strains and their associated metabolites as potential alleviators of UC. Notably, our experimental validation using a dextran sulfate sodium-induced UC mouse model demonstrated that the administration of Parabacteroides merdae ATCC 43,184 and N-Acetyl-D-mannosamine provided notable relief from colitis symptoms. In summary, our study underscores the potential of an integrative approach to identify novel therapeutic avenues for UC, paving the way for future targeted interventions.
Biosynthesis of UDP-alpha-N-Acetyl-d-mannosaminuronic Acid and CMP-beta-N-Acetyl-d-neuraminic Acid for the Capsular Polysaccharides of Campylobacter jejuni.[Pubmed:38382015]
Biochemistry. 2024 Mar 5;63(5):688-698.
Campylobacter jejuni is a human pathogen and a leading cause of food poisoning in North America and Europe. The exterior surface of the bacterial cell wall is attached to a polymeric coat of sugar molecules known as the capsular polysaccharide (CPS) that helps protect the organism from the host immune response. The CPS is composed of a repeating sequence of common and unusual sugar residues. In the HS:11 serotype of C. jejuni, we identified two enzymes in the gene cluster for CPS formation that are utilized for the biosynthesis of UDP-alpha-N-acetyl-d-mannosaminuronic acid (UDP-ManNAcA). In the first step, UDP-alpha-N-acetyl-d-glucosamine (UDP-GlcNAc) is epimerized at C2 to form UDP-alpha-N-Acetyl-D-mannosamine (UDP-ManNAc). This product is then oxidized by a NAD(+)-dependent C6-dehydrogenase to form UDP-ManNAcA. In the HS:6 serotype (C. jejuni strain 81116), we identified three enzymes that are required for the biosynthesis of CMP-beta-N-acetyl-d-neuraminic acid (CMP-Neu5Ac). In the first step, UDP-GlcNAc is epimerized at C2 and subsequently hydrolyzed to form N-Acetyl-D-mannosamine (ManNAc) with the release of UDP. This product is then condensed with PEP by N-acetyl-d-neuraminate synthase to form N-acetyl-d-neuraminic acid (Neu5Ac). In the final step, CMP-N-acetyl-d-neuraminic acid synthase utilizes CTP to convert this product into CMP-Neu5Ac. A bioinformatic analysis of these five enzymes from C. jejuni serotypes HS:11 and HS:6 identified other bacterial species that can produce UDP-ManNAcA or CMP-Neu5Ac for CPS formation.
Recent studies on non-invasive biomarkers useful in biliary atresia - a literature review.[Pubmed:37717264]
Acta Biochim Pol. 2023 Sep 17;70(3):475-480.
The aim of this review is to specify new potential reliable and non-invasive methods for the diagnosis of biliary atresia (BA) that could shorten the way to diagnose BA, and finally the surgical treatment. Apart from the biomarkers that have been proven helpful and are used nowadays in neonatal wards, there are several new potential biomarkers that researchers have found to be helpful in the diagnosis of biliary atresia. Circulating microRNAs, matrix metalloproteinase-7, stool proteins, interleukin-33, Th17-associated cytokines, urinary metabolomics, anti-smooth muscle antibodies, heat shock proteins 90 and positive biliary epithelial cells CD56 are among those presented in this summary. These markers may play a new significant role in BA diagnosis. The described methods include Nomogram, Circulating microRNAs (miRNAs), Matrix metalloproteinase-7 (MMP-7), Stool proteins, Interleukin-33 (IL-33), Th17-associated cytokines, Alpha-aminoadipic acid and N-Acetyl-D-mannosamine in urine, Anti-smooth muscle antibodies (ASMA), Heat shock proteins 90 (HSP90), Positive biliary epithelial cells CD56.
Escherichia coli BL21(DE3) optimized deletion mutant as the host for whole-cell biotransformation of N‑acetyl‑D‑neuraminic acid.[Pubmed:37688676]
Biotechnol Lett. 2023 Dec;45(11-12):1521-1528.
N‑Acetyl‑D‑neuraminic acid (Neu5Ac) is the crucial compound for the chemical synthesis of antiflu medicine Zanamivir. Chemoenzymatic synthesis of Neu5Ac involves N-acetyl-D-glucosamine 2-epimerase (AGE)-catalyzed epimerization of N-acetyl-D-glucosamine (GlcNAc) to N-Acetyl-D-mannosamine (ManNAc), and aldolase-catalyzed condensation between ManNAc and pyruvate. Host optimization plays an important role in the whole-cell biotransformation of value-added compounds. In this study, via single-plasmid biotransformation system, we showed that the AGE gene BT0453, cloned from human gut microorganism Bacteroides thetaiotaomicron VPI-5482, showed the highest biotransformation yield among the AGE genes tested; and there is no clear Neu5Ac yield difference between the BT0453 coupled with one aldolase coding nanA gene and two nanA genes. Next, Escherichia coli chromosomal genes involved in substrate degradation, product exportation and pH change were deleted via recombineering and CRISPR/Cas9. With the final E. coli BL21(DE3) DeltananA Deltanag DeltapoxB as host, a significant 16.5% yield improvement was obtained. Furthermore, precursor (pyruvate) feeding resulted in 3.2% yield improvement, reaching 66.8% molar biotransformation. The result highlights the importance of host optimization, and set the stage for further metabolic engineering of whole-cell biotransformation of Neu5Ac.